The 8 most recent market catalysts affecting $CLBT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $16
JP Morgan's decision to lower Cellebrite DI's price target from $20 to $16, while keeping an 'Overweight' rating, signals a recalibration of the analyst's valuation model. This cou…
Aug 13, 2026
Market Technicals
Bullish
Impact 55
12 Information Technology Stocks Moving In Thursday's Intraday Session
This 8-K filing, generated by Benzinga's automated content engine, serves as a snapshot of intraday trading activity for a selection of information technology stocks. It highlights…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 95
Cellebrite DI shares are trading lower after the company reported worse-than-expected Q2 sales results and issued Q3 sales guidance below estimates. Also, the company cut its FY26 sales guidance below estimates.
This headline represents a major corporate catalyst for Cellebrite DI (CLBT). The combination of a Q2 sales miss, lower-than-expected Q3 guidance, and a significant cut to long-ter…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 75
Cellebrite DI Lowers FY2026 Sales Guidance from $565.000M-$571.000M to $555.000M-$561.000M vs $568.048M Est
Cellebrite DI (CLBT) has announced a reduction in its sales guidance for fiscal year 2026, moving from an initial range of $565.000M-$571.000M to a new range of $555.000M-$561.000M…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 75
Cellebrite DI Sees Q3 Sales $145.000M-$148.000M vs $150.298M Est
Cellebrite DI (CLBT) announced Q3 sales guidance of $145 million to $148 million, which is notably lower than the analyst consensus estimate of $150.298 million. This downward revi…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 65
Cellebrite DI Q2 Adj. EPS $0.11, Inline, Sales $131.138M Miss $131.874M Estimate
Cellebrite DI (CLBT) announced its Q2 earnings, reporting an adjusted EPS of $0.11, which aligned with analyst consensus. However, the company's sales of $131.138 million missed th…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
DA Davidson Maintains Buy on Cellebrite DI, Raises Price Target to $22
DA Davidson analyst Rudy Kessinger has maintained a 'Buy' rating on Cellebrite DI (CLBT) and raised the price target from $20 to $22. This action signals a positive outlook from a …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.